Atrial Fibrillation Drugs Market Size, Share and Trends 2024 to 2034

Atrial Fibrillation Drugs Market Size and Forecast 2024 to 2034

The global atrial fibrillation drugs market size is expected to be valued at USD 15.59 billion in 2024 and is anticipated to reach around USD 20.99 billion by 2034, expanding at a solid CAGR of 3.02% over the forecast period 2024 to 2034. The North America atrial fibrillation drugs market size reached USD 25.88 billion in 2023. The increasing demand is due to high incidences of AF, a growing population of elderly, an improved health care system, and better diagnosis and management of the disease are driving the atrial fibrillation drugs market.

Atrial Fibrillation Drugs Market Key Takeaways

• North America led the global atrial fibrillation drugs market with the largest market share of 45% in 2023.
• Asia Pacific is anticipated to grow notably in the market during the forecast period.
• By products, the anticoagulant drugs segment accounted for the biggest share of the market in 2023.
• By products, the antiarrhythmic drugs segment is expected to witness significant growth in the market during the forecast period.
• By atrial fibrillation type, the paroxysmal segment held the largest share of the market in 2023.
• By atrial fibrillation type, the persistent segment is expected to grow at the fastest rate in the market over the forecast period.
• By route of administration, the oral segment dominated the global market in 2023.
• By route of administration, the injectable segment is estimated to grow significantly in the market during the forecast period.
• By application, the heart rhythm control segment generated the biggest share of the market in 2023.
• By application, the heart rate control segment is expected to grow significantly in the market during the forecast period.
• By end-use, the hospital segment dominated the global market in 2023.
• By end-use, the cardiac center segment is anticipated to grow significantly during the forecast period.

U.S. Atrial Fibrillation Drugs Market Size and Growth 2024 to 2034

The U.S. atrial fibrillation drugs market size was exhibited at USD 18.12 billion in 2023 and is projected to be worth around USD 29.69 billion by 2034, poised to grow at a CAGR of 4.59% from 2024 to 2034.

North America led the global atrial fibrillation drugs market in 2023, owing to the strong healthcare industry of the region, high spending on healthcare, and the availability of modern technological facilities, which add to the dominating market of this region. The incidence of atrial fibrillation is rather high, and it is most prevalent in elderly patients, thereby increasing the market’s potential for drug and therapeutic solutions.

• By 2030, an estimated 12.1 million people in the United States will be affected by the condition. With the aging population, demand for AFib treatment is expected to increase in the coming years.
• In October 2023, Milestone Pharmaceuticals submitted a new drug application (NDA) to the U.S. FDA for Etripamil, a nasal spray developed for patients suffering from atrial fibrillation and paroxysmal supraventricular tachycardia (PSVT).

Asia Pacific is anticipated to grow notably in the atrial fibrillation drugs market during the forecast period due to factors such as the rising occurrence of atrial fibrillation and the aging population escalating the high rate of AF patients and the need for treatment. This region also has an increasing patient population with chronic diseases, i.e., hypertension and diabetes, which are associated risk factors for AF.

Countries, including China, India, and Japan, are expected to focus on enhancing the healthcare facilities and availability of various elevated procedures and other specialized services, such as specialized clinics and cardiac centers.

• According to a report, Economist Impact, published by Johnson & Johnson in 2021, an estimated 72.0 million people will suffer from Afib in Asia Pacific by 2050. By 2050, it is estimated that 49 million men and 23 million women in the region will carry a diagnosis of AFib.

Market Overview

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. It is the top cardinal cause of stroke. Risk factors of AF include age, hypertension, heart and lung disorders, congenital heart disease, and excessive alcohol intake. While atrial fibrillation may be a lifelong condition, certain treatments and risk-reducing approaches were designed to prevent the worsening of the condition or to prevent the development of a stroke in patients.

• According to an article published in the National Center for Biotechnology Information in 2021, the prevalence of atrial fibrillation is estimated to be around 37.5 million across the globe and is projected to increase by more than 60% by the year 2050.

Treatments for atrial fibrillation include medicines to control heart rate and reduce the risk of stroke and procedures to restore normal heart rhythm. Treatments include rate control medication, cardioversion, ablation, rhythm control medication, anticoagulation, and other interventional cardiac procedures.

Common Medications for Atrial Fibrillation

How is AI Changing the Atrial Fibrillation Drugs Market?

Identifying atrial fibrillation at an early stage prevents other cardiac complications, such as strokes and other related heart problems, and is a crucial step in the atrial fibrillation drugs market. In addition, AF and AI research is a fast-growing field in healthcare research and development. Specifically, Eden et al. developed an AI that will forecast atrial fibrillation within 31 days with the sinus rhythm ECGs of outpatients. AF is a well-known stroke cause. It prevails in millions of participants and is often difficult to identify. This strategic model of presenting clinical artificial intelligence solutions for physicians enables the capability to predict cardiovascular diseases and conditions.

• In June 2024, Tempus obtained 510(k) clearance from the U.S. FDA for Tempus ECG-AF the company's AI-based algorithm for detecting patients who are at high risk of developing AF.

Atrial Fibrillation Drugs Market Growth Factors

• In the atrial fibrillation drugs market, a large number of AF cases, particularly among the aging population, run demand for effective treatments.
• Satisfactory healthcare centers enhance available advanced healthcare services in diagnosing and treating AF.
• The research activities result in the evolution of different and better treatment products.
• Rising awareness and education among the population and professionals about AF and high rates of treatment usage.

Market Scope

Market Dynamics

Driver

Increase in incidence of cardiovascular diseases

Atrial fibrillation is a common cardiac arrhythmia that is associated with an increased risk of cardiovascular disease. Thus, an increasing prevalence of cardiovascular conditions drives the atrial fibrillation drugs market. It has been noted that there has been an increasing number of people with atrial fibrillation. The probability of a stroke is five-fold higher in patients who have already been diagnosed with atrial fibrillation compared with the general population.

Atrial fibrillation is the most common and worrisome cardiac arrhythmia that is known to have a poor prognosis because of the higher risks of stroke and death. While formerly anticoagulation therapy for cardiovascular diseases has always been related to the presentation of AF, growing data shows high rates of the disease in patients with non-cardiovascular disorders like cancer, sepsis, chronic obstructive pulmonary disease, obstructive sleep apnea, and chronic kidney disease.

Comorbidities Associated with Atrial Fibrillation

• Obesity
• Type 2 diabetes
• Chronic kidney disease
• Heart failure
• Coronary artery disease
• Congenital heart disease
• Lung diseases, like chronic obstructive pulmonary disease (COPD)
• Sleep apnea
• Hyperthyroidism
• Restraint
• Adverse drug side effects

Side effects are a concern in the atrial fibrillation drugs market because their consequences affect patient safety and outcomes significantly. Some of the drugs prescribed to treat AF include anticoagulants and antiarrhythmic drugs, which may cause side effects such as a high risk of bleeding, gastrointestinal disorders, renal/ hepatic problems, or other dysfunctions. These are distributed with the following by the pharmaceutical industry: regulatory scrutiny, pharmacovigilance, and constant research for safer drugs. These are important to enhance patients’ outcomes and address challenges arising from the management of AF.

Blood thinners have several possible side effects. These include

• Sick, weak, faint, or dizzy
• Red, dark brown, or black stools or urine
• Gums bleed
• Pain or swelling
• Difficulty in breathing
• Fever or illness

Opportunity

Personalized management of atrial fibrillation

The continuous changes in the management of AF are a good opportunity to improve the care of the patients by developing better treatment plans in the atrial fibrillation drugs market. Perhaps the most significant advantage is that clinicians can offer treatments that are even more accurate by validating parameters, which include the type of AF presentation, clinical factors, ECG analysis, and cardiac imaging. This marks the potential for further inclusion of these new biomarkers to improve patient-specific management strategies responsive to the specific pattern exhibited by each individual.

Products Insights

The anticoagulant drugs segment accounted for the biggest share of the atrial fibrillation drugs market in 2023. Anticoagulants, useful in managing atrial fibrillation patients, are used to minimize the formation of clots and thus decrease the likelihood of stroke. These are now preferred over warfarin for patients with nonvalvular atrial fibrillation.

• In June 2022, Eagle Pharmaceuticals submitted a new drug application (NDA) to the U.S. FDA for landiolol, a beta-1 adrenoceptor blocker intended to be used as a short-acting agent for the relief of ventricular rate in patients with Afib, an atrial flutter, and supraventricular tachycardia.

The antiarrhythmic drugs segment is expected to witness significant growth in the atrial fibrillation drugs market during the forecast period. The most common type of atrial arrhythmia is called atrial fibrillation. With advancing age, the prevalence of AF rises, and more patients receive antiarrhythmic drugs (AADs), an antiarrhythmic medication that could be used in the treatment of AF and atrial flutter. It also has the potential to decrease the hospital readmissions of patients with high-risk AF.

Atrial Fibrillation Type Insights

The paroxysmal segment held the largest share of the atrial fibrillation drugs market in 2023. If recurrent AF reverts spontaneously, it is called paroxysmal AF. They last less than one week and, most times, do not require any treatment since they are temporary episodes. Many people experience influenza-like symptoms even during the short time of AF, and patients experiencing paroxysmal AF remain at increased risk of stroke compared to people without AF at all.

• In July 2022, OFS Capital Limited completed its acquisition of Lantern to strengthen its oil service sector presence as Lantern’s name was changed to OFS Lantern Limited.
• In March 2024, Biosense Webster will approach the U.S. Food and Drug Administration for approval of the varipulse system to treat paroxysmal atrial fibrillation.

The persistent segment is expected to grow at the fastest rate in the atrial fibrillation drugs market over the forecast period. When AF continues, requiring either pharmacological or electrical conversion back to sinus rhythm, it is called persistent AF. The episodes last more than one week and generally require specialized treatment to either slow the heart rate down or restore the Afib to normal sinus rhythm. In this case, the episodes are more than seven days.

• In December 2023, Boston Scientific started the guard clinical trial on the far pulse pulsed field ablation system for the first-line treatment of persistent atrial fibrillation.

Route of Administration Insights

The oral segment dominated the global atrial fibrillation drugs market in 2023. Oral drug therapies have been the most prescribed drug therapies for deciding atrial strokes due to their efficacy in the prevention of clotting formation, which in turn fuel the market growth. These drugs are available in tablet or capsule forms, which may enhance patients' ability to stick to their prescriptions.

• An NHS England press release in November 2023 said that since 2022, some 460,000 people have started on direct oral anticoagulants (DOACs), which have prevented around 17,000 strokes and 4000 deaths in England.

The injectable segment is estimated to grow significantly in the atrial fibrillation drugs market during the forecast period. Injectable drugs, such as low molecular weight heparins, for example, using enoxaparin or unfractionated heparin, are in a position to offer immediate anticoagulant necessities, normally in the hospital settings or for some circumstances of specific clients. Injectable options can either be subcutaneously or intravenously given, and professional staff can be required to give them. In most cases, they come with specific monitoring. Lanoxin is an injectable drug used to treat patients with atrial fibrillation, AF for short, and heart failure. It increases the force of the contraction of the heart and reduces the rate of rapid electrical activity in your heart.

Application Insights

The heart rhythm control segment generated the biggest share of the atrial fibrillation drugs market in 2023. The strategy of restoring rhythm control, either pharmacological or electrical, pharmacological or electrical is a condition, symptom status, age, and other comorbidities. Such strategies can include cardioversion and the administration of antiarrhythmic drugs (AADs), as well as catheter ablation.

The heart rate control segment is expected to grow significantly in the atrial fibrillation drugs market during the forecast period. For all the asymptomatic patients with AF, rate control is the best strategy. In many patients, rate control might be maintained for the long term, mainly where rhythm control is ineffective, not advised, or has no possibility of success. In many cases, simple and adequate rate control can effectively alleviate the symptoms related to atrial fibrillation. Rate control is very practical, requires a short time for initiation and monitoring, and no significant complications resulting from AF and related to the treatment have been observed.

End-use Insights

The hospital segment dominated the global atrial fibrillation drugs market in 2023. This growth is due to high surgical procedures that are carried out within hospitals, immense focus on skilled personnel and appropriate surgical implements. Also, the increase in the prevalence of chronic diseases that cause more patients to be admitted to hospitals will help fuel this segment.

• Approximately 454,200 patients are hospitalized annually in the U.S., mainly due to AFib, which makes hospitals a critical factor in the treatment and management of the condition.

The cardiac center segment is anticipated to grow significantly in the atrial fibrillation drugs market during the forecast period. There are certain reasons behind it, such as the inclination towards surgeries in specialty clinics and the growing incidence of atrial fibrillation, which requires specialty care. These cardiac centers, with their specific focus and better technology, are much better placed to address this demand.

Atrial Fibrillation Drugs Market Companies

• Johnson & Johnson
• Pfizer
• Sanofi
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo
• AstraZeneca

Recent Developments

• In June 2024, Alembic Pharmaceuticals Limited declared that they got U.S. FDA approval for their ANDA for dabigatran etexilate capsules.
• In June 2024, Kardium announced USD 104 million in new financing for innovative atrial fibrillation treatment dabigatran etexilate capsules are indicated for the reduction of the risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients.
• In November 2023, Bayer AG broadened its phase 3 clinical trial program for the new drug candidate Asundexian. The company is exploring the possibilities of using the said drug for the treatment of affected patients who are at an increased risk of stroke or embolism.
• In March 2023, Bristol Myers Squibb initiated a pivotal phase 3 Librexia trial program with Janssen Pharmaceuticals for an oral factor Xia (FXIa) inhibitor milvexian antithrombotic. The trial is expected to compare Milvexian to Apixaban for the prevention of stroke amongst patients with AF.
• In June 2022, Apotex Inc. recreated the Eliquis brand of Apixaban through APO-Apixaban tablets in Canada. The drug is in tablets and comes in two different strengths, which are 2. 5 mg and 5 mg.

Segments Covered in the Report

By Products

• Antiarrhythmic Drugs
• Anticoagulant Drugs
• Vitamin K Antagonists
• Novel Oral Anticoagulants

By Atrial Fibrillation Type

• Paroxysmal
• Persistent
• Permanent

By Route of Administration

• Oral
• Injectable

By Application

• Heart Rhythm Control
• Heart Rate Control

By End-use Hospitals

• Cardiac Centers
• Ambulatory Surgical Centers

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa